文献速递肿瘤 PET/CT

68Ga-Pentixafor靶向CXCR4的PET/CT在华氏巨球蛋白血症患者中优于18F-FDG

Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
PubMed 文献 · Clin Nucl Med · 2018-01-01

一例69岁女性华氏巨球蛋白血症(WM)患者接受18F-FDG和68Ga-Pentixafor PET/CT评估。68Ga-Pentixafor PET/CT显示骨髓和淋巴结广泛受累且放射性浓聚强烈,而18F-FDG PET/CT中病灶示踪剂摄取显著较低。作者认为68Ga-Pentixafor PET/CT在检测WM病灶方面优于18F-FDG,未来研究中有望成为评估WM肿瘤负荷的影像方法。

要点

  • 68Ga-Pentixafor PET/CT显示WM患者骨髓和淋巴结广泛受累且放射性浓聚强烈。
  • 同患者18F-FDG PET/CT中病灶示踪剂摄取显著较低。
  • 作者认为68Ga-Pentixafor PET/CT在检测WM病灶方面优于18F-FDG,未来研究中有望用于评估WM肿瘤负荷。

核心结论

  • 作者认为68Ga-Pentixafor PET/CT在该患者中检测WM病灶优于18F-FDG,未来研究中有望成为评估WM肿瘤负荷的影像方法。

研究设计与样本

  • 一例69岁女性华氏巨球蛋白血症(WM)患者接受18F-FDG和68Ga-Pentixafor PET/CT评估。

主要发现

  • 68Ga-Pentixafor PET/CT显示WM广泛累及骨髓和淋巴结,放射性浓聚强烈。
  • 18F-FDG PET/CT中病灶示踪剂摄取显著较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 69-year-old woman diagnosed with Waldenström macroglobulinemia (WM) was referred for F-FDG and Ga-Pentixafor PET/CT for evaluation of the disease. Extensive involvement of WM with intense radioactivity in the bone marrow and lymph nodes was found in Ga-Pentixafor PET/CT. However, in F-FDG PET/CT, the lesions showed significantly lower tracer uptake. Given the superiority of Ga-Pentixafor in detecting WM lesions to F-FDG in this patient, Ga-Pentixafor PET/CT might be a promising imaging modality in assessment of tumor burden of WM in future studies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Luo Y, Pan Q, Feng J, et al. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia. Clin Nucl Med. 2018. PMID: 29742593. doi:10.1097/RLU.0000000000002131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。